Gliptalex M 50/500 MG Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps in achieving optimal blood glucose regulation. Gliptalex M is prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is particularly beneficial for patients who require dual mechanism therapy to control hyperglycemia. The tablet should be administered orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Gliptalex M 50/500 MG Tablet offers an effective and well-tolerated option for comprehensive glycemic management in type 2 diabetes.